GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target B7-H3 expressing solid tumor cancers.
A Phase 1 trial of GTB-5550 for multiple solid tumors is planned for 2026.
The company is also conducting a Phase 1 study of GTB-3650 in myeloid blood cancers, with the next data readout expected in the first half of 2026.
GT Biopharma reported a preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025, which is expected to extend its cash runway into the third quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.